MedTrace Logo

Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer

NCT00160901 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2007-04-19

No results posted yet for this study

Summary

The purpose of this study is to determine wether a complementary therapy consisting of a combined medication of selenium, milk thistle, goldenrod and bromelain and a consultation concerning nutrition and physical activity can reduce side effects of a chemotherapy in breast cancer patients.

Conditions

Interventions

DRUG

two complex naturopathic add-on therapies, leaflet 5-a-day

Sponsors & Collaborators

  • Hector-Stiftung

    collaborator OTHER

  • Cefak KG, Kempten

    collaborator UNKNOWN

  • Ursapharm, Saarbrücken

    collaborator UNKNOWN

  • Schwabe-Wenex International Ltd

    collaborator INDUSTRY

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Cornelia U. von Hagens, MD · Department of Complementary and Integrative Medicine Women's Hospital, University of Heidelberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Completion
2005-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160901 on ClinicalTrials.gov